3 April 2024 - Today, the US FDA approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with ...
2 April 2024 - RemeGen has obtained fast track designation by the US FDA recently for its innovative BLyS/APRIL dual-target ...
2 April 2024 - Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, completion of the rolling submission of ...
1 April 2024 - Site initiations scheduled for April; patient dosing expected to begin in Q2 ,2024. ...
2 April 2024 - Fast track designation for NOX-A12 follows recently announced FDA clearance of investigational new drug application for Phase ...
2 April 2024 - Application based on results from the TROPION-Breast01 Phase 3 trial. ...
1 April 2024 - Approval of first in class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase ...
1 April 2024 - Eisai and Biogen announced today that Eisai submitted to the US FDA a supplemental biologics license ...
1 April 2024 - Target action date set for 19 November 2024. ...
26 March 2024 - Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and ...
29 March 2024 - Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be ...
28 March 2024 - D&D Pharmatech said Thursday that DD01, an injectable treatment for metabolic-associated steatohepatitis (MASH) being developed by ...
26 March 2024 - PDUFA date set for 24 September 2024. ...
27 March 2024 - Once daily oral HIF-PH inhibitor activates physiologic response to manage anaemia. ...
26 March 2024 - PDUFA action date set for 26 September 2024. ...